The insect growth regulator tebufenozide (MIMIC 2LV) was tested to examine its impact on the Douglas-fir tussock moth, Orgyia pseudotsugata (McDunnough) (Lepidoptera: Lymantriidae). Laboratory tests gave an estimated concentration of 1.26 ppm of the compound to achieve 50% population mortality (LC50) for second-instar O. pseudotsugata. At the highest concentration tested, tebufenozide resulted in significant larval mortality within 7 d with an estimated time to 50% population mortality (LT50) of 6.3 d. A field comparison of tebufenozide with diflubenzuron (Dimilin 4L) and Bacillus thurengiensis var. kurstaki (Btk, FORAY 48B) was also conducted. There was no significant difference in larval mortality within field plots that were treated with diflubenzuron (42.4%) or Btk (44.8%). Larval mortality in the tebufenozide-treated plots (56.8%) was also similar to the mortality in the diflubenzuron and Btk treatments. All three treatments resulted in more larval mortality than that measured in untreated control plots (11.2%). Both tebufenozide and diflubenzuron treatments resulted in significantly more mortality (55.0% and 40.0%, respectively) to larvae-fed treated foliage 3 wk after application than was measured for larvae-fed foliage from untreated trees (11.0%). There was no significant difference among the treatments in the percentage of host trees in the overstory that sustained >25% defoliation, and all three treatments resulted in less defoliation than was measured in the control plots. There was no significant difference among the treatments in the percentage of host trees in the understory that sustained >25% defoliation.
You have requested a machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Neither BioOne nor the owners and publishers of the content make, and they explicitly disclaim, any express or implied representations or warranties of any kind, including, without limitation, representations and warranties as to the functionality of the translation feature or the accuracy or completeness of the translations.
Translations are not retained in our system. Your use of this feature and the translations is subject to all use restrictions contained in the Terms and Conditions of Use of the BioOne website.
Vol. 96 • No. 2